Rapid RNA sequencing of coronavirus for public health surveillance and transmission

  • Funded by Alberta Innovates, Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 170705

Grant search

Key facts

  • Disease

    COVID-19
  • Known Financial Commitments (USD)

    $561,376.91
  • Funder

    Alberta Innovates, Canadian Institutes of Health Research (CIHR)
  • Principle Investigator

    Pending
  • Research Location

    Canada, Americas
  • Lead Research Institution

    University of Alberta
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    Gender

  • Study Subject

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

There is an ongoing worldwide outbreak of the COVID-19 coronavirus. As of February 18 2020, nearly 73,500 cases have been identified and 1,875 deaths reported. To prevent further spread and to understand how the COVID-19 virus is spreading, where it came from, and when it likely jumped from animal to humans, the genome sequences of these viruses have been instrumental in providing insights. So far, Canada has reported 8 cases of COVID-19 (5 in BC; 3 in ON). However, no Canadian genomes have been made publicly available. In contrast, over 102 genomes have been released from several other countries including China, Taiwan, Japan, Australia and the United States. Here, the Public Health Laboratory in Alberta, Edmonton and Calgary and the National Microbiology Laboratory in Winnipeg have teamed up with genomics, bioinformatics, microbiology and infectious disease experts to address this challenge. We are verifying a direct RNA sequencing method capable of accelerated inexpensive sequencing of COVID-19 virus genomes. We aim to roll out this rapid method into Canada's frontline operations, along with direct analysis to promote global sharing and uptake of needed genome information. The lab methodology and data analysis will be openly available to help the global response in combating this disease.